Hastalarınız için Hızlı ve Doğru Karar Alma
Digistain, Evre 1 veya 2, HER2–, ER+ veya 3’e kadar malign lenf düğümüne sahip invaziv meme kanseri tanısı almış hastalarda klinisyenlere sonraki 5-10 years for patients diagnosed with invasive breast cancer who are Stage 1 or 2, HER2-, ER+ or equal to or less than 3 malignant lymph nodes.
MHRA onaylı teknoloji, 1.500’den fazla onkologun katkısıyla geliştirilmiş ve önde gelen kanser merkezlerinde NICE onaylı geleneksel tümör profilleme testleriyle altın standart eşdeğerliğini göstererek başarıyla denenmiştir.
Unlike genomic tests, Digistain measures markers at the protein level using a unique combination of optical scan technology and AI. It, therefore, avoids the quality control and reproducibility issues common to RNA isolation from formalin-fixed tissue.
Temel Özellikler
Adjuvan kemoterapi tedavi kararı almayı yönlendirmek için kolayca okunabilir ve uygulanabilir rapor
Yalnızca endokrin tedaviyle tedavi edildiğinde bireysel hasta riskini tahmin eder
Profiles a tumour in minutes with results returned very quickly so that information can be acted upon before a patient even leaves hospital
Dramatically lowers the cost per biopsy test
Advanced quality management and seamless integration into existing pathology workflows
Reduction in patient waiting times
0
%
Overall cost reduction through avoided chemotherapy
0
%
Multi-site reproducibility with routinely trained lab technicians
0
%
Digistain® Prognostik Skoru
Bugün dünya genelindeki hastanelerde kullanılan birinci nesil genomik testlerin aksine Digistain®, markörleri protein düzeyinde ölçmek için biyolojik olarak aşağı akımda çalışmaktadır. It, therefore, avoids the quality control and reproducibility issues common to RNA isolation from formalin-fixed tissue.
The advantage of working downstream is that Digistain’s unique approach is much closer to the patient outcome than biologically upstream laboratory protocols and is robust to clinical protocol variab
In a landmark peer-reviewed validation study of 801 patients, Digistain’s risk stratification report demonstrated clinically relevant performance in its intended population.
Risk Actionable Information in Under 1 Hour
Subscribe to leading news and insights
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.